welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
-
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal CancersPrimary Objective: - To determine whethe...
-
Laparoscopic Restorative Proctocolectomy: Case-Matched Comparative Study with Open Restorative ProctocolectomyPURPOSE : A laparoscopic approach to res...
-
Fate of the Rectal Stump After Colectomy and Ileorectal Anastomosis for Familial Adenomatous PolyposisThe justification of colectomy and ileor...
-
Hereditary Colorectal Cancerhttps://www.fapvoice.com/wp-content/uplo...
-
18F-FES PET/CT in Imaging Patients With Desmoid TumorsThis pilot clinical trial studies fluori...
-
Familial Adenomatous Polyposis in Pediatrics: Natural History, Emerging Surveillance and Management Protocols, Chemo...Familial adenomatous polyposis (FAP) is ...
-
Dual Focus NBI and pCLE in FAP Related Duodenal AdenomaBackground: Familial adenomatous pol...